Showing results (31-40 of 138) with videos related to

Sort By:
Pageof 14
Current Pharmaceutical Design|December 9, 2015
Pharmacogenomics of Oral Antithrombotic DrugsFlavia Storelli, Youssef Daali, Jules Desmeules, et al.
Frontiers in Pharmacology|January 10, 2017
Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic DefectKuntheavy Ing Lorenzini, Youssef Daali, Pierre Fontana, et al.
Current Drug Metabolism|July 17, 2015
Evidence-Based Choice of P2Y12 Inhibitors in End Stage Renal Disease Patients: A Mini-ReviewYassine Bouatou, Caroline Flora Samer, Pierre Fontana, et al.
Clinical Pharmacokinetics|April 19, 2018
Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical PerspectivesFlavia Storelli, Caroline Samer, Jean-Luc Reny, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 7, 2010
How organic anions accumulate in hepatocytes lacking Mrp2: evidence in rat liverPhilippe Millet, Marcelle Moulin, Bruno Stieger, et al.
Pediatric Research|October 11, 2019
Toward precision medicine in pediatric population using cytochrome P450 phenotyping approaches and physiologically based pharmacokinetic modelingGaëlle Magliocco, Frédérique Rodieux, Jules Desmeules, et al.
Clinical Pharmacokinetics|June 29, 2019
Towards Personalized Antithrombotic Treatments: Focus on P2Y12 Inhibitors and Direct Oral AnticoagulantsJean Terrier, Youssef Daali, Pierre Fontana, et al.
Pharmaceuticals (Basel, Switzerland)|August 29, 2024
Guidance on Selecting Optimal Steady-State Tacrolimus Concentrations for Continuous IV Perfusion: Insights from Physiologically Based Pharmacokinetic ModelingRomain Martischang, Argyro Nikolaou, Youssef Daali, et al.
Clinical Pharmacology and Therapeutics|July 30, 2024
Phenoconversion Due to Drug-Drug Interactions in CYP2C19 Genotyped Healthy VolunteersKenza Abouir, Nadia Exquis, Yvonne Gloor, et al.
European Journal of Pain (London, England)|March 15, 2020
GABAergic modulation of secondary hyperalgesia: A randomized controlled 4-way crossover trial with the α2-subunit preferring GABA positive allosteric modulator, N-desmethyl-clobazam in healthy volunteersAlain Matthey, Youssef Daali, François Curtin, et al.
Pageof 14